- Home
- MEGI vs TLRY Comparison
MEGI vs TLRY Comparison
Compare MEGI & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGI | TLRY |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 688.9M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MEGI | TLRY |
|---|---|---|
| Price | $15.31 | $4.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $72.33 |
| AVG Volume (30 Days) | 125.3K | ★ 3.4M |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | N/A | $19.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.42 | $0.39 |
| 52 Week High | $15.89 | $15.70 |
Technical Indicators
Market Signals| Indicator | MEGI | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 33.33 |
| Support Level | $14.61 | $1.14 |
| Resistance Level | $15.39 | $5.71 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 75.45 | 15.71 |
Price Performance
Historical ComparisonAbout MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.